首页> Annals of clinical and translational neurology> Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism.

Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism.

导出 LinkOut

翻译打印收藏纠错

第一作者： Ho Jin,Kim

第一单位： Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, South Korea.

作者： Ho Jin,Kim ^[1] ; Orhan,Aktas ^[2] ; Kristina R,Patterson ^[3] ; Schaun,Korff ^[3] ; Amy,Kunchok ^[4] ; Jeffrey L,Bennett ^[5] ; Brian G,Weinshenker ^[6] ; Friedemann,Paul ^[7] ; Hans-Peter,Hartung ^[8] ; Daniel,Cimbora ^[3] ; Michael A,Smith ^[3] ; Nanette,Mittereder ^[3] ; William A,Rees ^[3] ; Dewei,She ^[3] ; Bruce A C,Cree ^[9]

作者单位： Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, South Korea. ^[1] Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany. ^[2] Horizon Therapeutics, Illinois, Deerfield, USA. ^[3] Department of Neurology, Mellen Center for Multiple Sclerosis, Cleveland Clinic, Ohio, Cleveland, USA. ^[4] Department of Neurology, Programs in Neuroscience and Immunology, University of Colorado School of Medicine, Anschutz Medical Campus, Colorado, Aurora, USA. ^[5] Department of Neurology, University of Virginia, Virginia, Charlottesville, USA. ^[6] Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité, Universitätsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. ^[7] Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.;Brain and Mind Centre, University of Sydney, New South Wales, Sydney, Australia.;Department of Neurology, Medical University Vienna, Vienna, Austria.;Department of Neurology, Palacky University in Olomouc, Olomouc, Czech Republic. ^[8] Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, California, San Francisco, USA. ^[9]

医学主题词人类(Humans);视神经脊髓炎(Neuromyelitis Optica);水通道蛋白质4(Aquaporin 4);免疫球蛋白G(Immunoglobulin G);受体, IgG(Receptors, IgG)

DOI 10.1002/acn3.51911

PMID 37804003

发布时间 2024-02-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Annals of clinical and translational neurology

2023年10卷12期

2413-2420页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Annals of clinical and translational neurology

2023年10卷12期

2413-2420页

检索历史清除

Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism.

Annals of clinical and translational neurology

相似文献

同项目论文

Annals of clinical and translational neurology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism.

Annals of clinical and translational neurology

相似文献

同项目论文

Annals of clinical and translational neurology

相关期刊

检索历史清除